Страна: Канада
мова: англійська
Джерело: Health Canada
METFORMIN HYDROCHLORIDE
SEPTA PHARMACEUTICALS INC
A10BA02
METFORMIN
850MG
TABLET
METFORMIN HYDROCHLORIDE 850MG
ORAL
100
Prescription
BIGUANIDES
Active ingredient group (AIG) number: 0101773002; AHFS:
APPROVED
2015-08-19
_Page 1 of 30_ PRODUCT MONOGRAPH PR SEPTA-METFORMIN Metformin Hydrochloride , Mfr Std 500 mg and 850 mg Oral Antihyperglycemic Agent Septa Pharmaceuticals Inc. 7490 Pacific Circle, Unit # 1 Mississauga ON L5T 2A3 Canada DATE OF PREPARATION: AUGUST 7, 2015 SUBMISSION CONTROL NO.: 185797 _Page 2 of 30_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................ 3 INDICATIONS AND CLINICAL USE .................................................................................. 3 CONTRAINDICATIONS ........................................................................................................ 3 WARNINGS AND PRECAUTIONS ...................................................................................... 5 ADVERSE REACTIONS ....................................................................................................... 10 DRUG INTERACTIONS ....................................................................................................... 11 DOSAGE AND ADMINISTRATION ................................................................................... 14 OVERDOSAGE ...................................................................................................................... 14 ACTION AND CLINICAL PHARMACOLOGY ................................................................ 15 STORAGE AND STABILITY............................................................................................... 15 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................... 15 PART II: SCIENTIFIC INFORMATION ............................................................................... 16 PHARMACEUTICAL INFORMATION ............................................................................. 16 CLINICAL TRIALS ............................................................................................................... 17 DETAIL Прочитайте повний документ